[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"ClinLogic LLC\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":62},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,39],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":28,"startDateStruct":31,"completionDateStruct":33,"leadSponsor":35,"locationsCount":38},"100354626","strategic-targeting-for-optimal-prevention-of-cancer-100354626",false,"NCT03897374","Strategic Targeting for Optimal Prevention of Cancer","STOP-Cancer","Inclusion Criteria:\n\n* Study subjects may be included in the Clinical Trial if they meet all of the following inclusion criteria:\n\n  * individuals, ages 65 years or older;\n  * must have met medical necessity for hereditary cancer genomic testing and allowed the physician to test based on medical necessity;\n  * hereditary cancer diagnostic test was ordered by a physician related to individual subject care considerations.\n  * study subject has or had cancer\n  * study subject has at least one family member with cirrent or past cancer\n\nExclusion Criteria:\n\n* Study subjects will be excluded from the study if any of the following criteria apply: • study subject is currently hospitalized or incarcerated;\n\n  * study subject is unable to provide an accurate history due to mental incapacity\n  * study subject is currently abusing illicit and\u002For prescription drugs;","ALL","65 Years",{"count":19,"type":20},120000,"ESTIMATED","120 Days","OBSERVATIONAL","The primary goal of the study is to record data over the observation period to evaluate the clinical benefit of using hereditary cancer genomic diagnostics to assess overall hereditary genetic cancer risk profile and to help guide physicians to pursue preventative measures, which may lead to early detection and treatment of the condition.",[25],"Early Detection of Cancer","RECRUITING","2026-03-17",{"date":29,"type":30},"2026-03-19","ACTUAL",{"date":32,"type":30},"2025-03-26",{"date":34,"type":20},"2028-12-31",{"name":36,"class":37},"ClinLogic LLC","INDUSTRY",1,{"id":40,"slug":41,"hasResults":11,"nctId":42,"briefTitle":43,"officialTitle":44,"acronym":45,"eligibilityCriteria":46,"healthyVolunteers":47,"sex":16,"minAge":48,"maxAge":4,"enrollmentInfo":49,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":51,"conditions":52,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":54,"lastUpdatePostDateStruct":55,"startDateStruct":57,"completionDateStruct":59,"leadSponsor":61,"locationsCount":38},"100265691","reduction-of-adverse-drug-events-and-readmissions-100265691","NCT02738047","Reduction of Adverse Drug Events and Readmissions","Pharmacogenomic Test Assessment for Medication Management in the Advancement of Medicine","RADAR-PGX","INCLUSION CRITERIA\n\nPatients may be included in the Study if they meet all of the following inclusion criteria:\n\n1. Male or female patients of 25 years of age or older who are able to give their written Informed Consent to participate in a Clinical Study based on voluntary agreement with a thorough explanation of the patient's participation will be provided to them.\n2. Patient underwent PGx testing for alleles appropriate to the target drugs within the prior 120 days (\"index PGx test assessment\");\n3. Patient was receiving at least one medication known to be associated with allelic variation at the time of the (\"index PGx test assessment\"), including over-the- counter medications;\n4. Patient has a history of at least one TDAE over the 24-month period preceding the PGx test assessment, or has experienced inadequate efficacy from a target drug.\n\nEXCLUSION CRITERIA\n\nPatients will be excluded from the Study if any of the following criteria apply:\n\n1. Patient is currently hospitalized;\n2. Patient's medical and medication history is unavailable over the 120-day period preceding the PGx test assessment;\n3. Patient is unable to provide an accurate history due to mental Incapacity;\n4. Patient is known to have undergone prior PGx testing for genes specific to the target drug(s), exclusive of the PGx test relating to this Study.",true,"25 Years",{"count":50,"type":20},280000,"Pharmocogenomic test assessment in the medication regimen and disease management for patients under drugs known with genetic variation.",[53],"Pharmacogenomic Testing for Medication Management","2024-02-06",{"date":56,"type":30},"2024-02-07",{"date":58,"type":30},"2019-03-15",{"date":60,"type":20},"2026-12",{"name":36,"class":37},""]